Leads Biolabs' Novel Antibody Trial Offers New Hope for Esophageal Cancer

NANJING, China – March 09, 2026 – A pivotal clinical trial has commenced in China, offering a potential new lifeline for patients battling one of the nation's most prevalent and deadly cancers. Nanjing-based Leads Biolabs announced that the first patient has been dosed in a Phase II study of Opamtistomig (LBL-024), an innovative bispecific antibody for the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). The trial marks a significant step forward in the quest for more effective therapies against a disease with historically grim survival rates.

The study, led by esteemed oncologist Professor Shen Lin of Beijing Cancer Hospital, aims to evaluate the safety and efficacy of Opamtistomig in patients with locally advanced or metastatic ESCC. This development brings a novel immuno-oncology approach to the forefront of a major public health crisis.

The Unmet Need: China's Battle with Esophageal Cancer

Esophageal cancer casts a long shadow over China, which accounts for nearly half of all new cases and deaths from the disease worldwide. The predominant subtype, esophageal squamous cell carcinoma, ranks as the seventh most common cancer in the country. According to 2022 data from the World Health Organization's International Agency for Research on Cancer (IARC), China sees an estimated 224,000 new ESCC cases and 187,000 deaths annually.

The disease's insidious nature means most patients are diagnosed at an advanced stage, when the cancer has already spread, making treatment exceptionally difficult. While the advent of immune checkpoint inhibitors (ICIs) like sintilimab, when combined with traditional chemotherapy, has represented an improvement over chemotherapy alone, the benefits remain modest. Patients undergoing these current standard-of-care treatments have a median overall survival of only 12 to 17 months, and the five-year survival rate languishes between 10% and 30%. This stark reality underscores a pressing unmet medical need for breakthrough therapies that can offer patients a more substantial and durable chance at survival.

A Two-Pronged Attack: The Science Behind Opamtistomig

Opamtistomig represents a next-generation approach to immunotherapy, designed to overcome the limitations of existing treatments. It is a bispecific antibody, meaning it is engineered to bind to two different targets simultaneously. Developed on Leads Biolabs' proprietary X-Body platform, the drug is designed to execute a coordinated, two-pronged attack on cancer cells.

First, it blocks PD-L1, a protein that cancer cells often use to hide from the immune system. This action is similar to existing ICI drugs, effectively releasing the "brakes" on the body's T-cells. However, Opamtistomig goes a crucial step further by also activating a co-stimulatory receptor called 4-1BB on the surface of those T-cells. Activating 4-1BB acts like pressing the "gas pedal," promoting robust T-cell proliferation and reactivating exhausted immune cells.

This dual-action mechanism is intended to create a more potent and synergistic anti-tumor response than blocking PD-L1 alone. By simultaneously disabling the cancer's defenses and supercharging the immune attack, Opamtistomig has the potential to be effective even in immunologically "cold" tumors that are typically resistant to conventional immunotherapy. This approach marks a significant evolution from first-generation 4-1BB agonists, some of which were hampered by systemic toxicity or limited efficacy. By tethering the 4-1BB activation to PD-L1, which is highly expressed in the tumor microenvironment, Opamtistomig aims to concentrate its power where it's needed most, potentially improving both its effectiveness and safety profile.

Leads Biolabs' Strategic Push into Major Oncology Markets

While the ESCC trial is a new milestone, Opamtistomig is already a cornerstone of Leads Biolabs' pipeline, having demonstrated significant promise in other difficult-to-treat cancers. The drug is considered a potential first-in-class therapy for extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive malignancy with no globally accepted standard of care.

Its potential has been recognized by regulatory agencies worldwide. Opamtistomig has received Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA), as well as Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) and the European Commission for its development in EP-NEC. These designations are reserved for promising drugs that address serious, unmet medical needs and are designed to expedite the development and review process.

The launch of the ESCC trial represents a strategic expansion for the Nanjing-based biotech, moving its star asset into a significantly larger patient population with high commercial potential. It showcases the company's ambition to leverage its validated technology platforms and translate its scientific innovation into therapies that can make a global impact.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, highlighted the trial's importance. "ESCC is highly prevalent with poor prognosis in China," he stated in the company's announcement. "While immune-chemotherapy combinations have shown progress, the overall survival benefit remains very limited, necessitating breakthrough solutions. The dosing of the first ESCC patient with Opamtistomig marks a critical milestone... We anticipate it will overcome current immunotherapy limitations, delivering both higher response rates and prolonged survival benefits for patients."

The multi-center study will now gather crucial data on how this novel dual-targeting mechanism performs in the first-line setting for ESCC. Success in this trial could not only redefine the standard of care for this devastating disease in China but also solidify Leads Biolabs' position as a key innovator in the competitive global immuno-oncology landscape. As researchers and patients watch closely, the trial represents a tangible step toward turning the tide against one of Asia's most formidable cancers.